Is scale-up worth it? Challenges in economic analysis of diagnostic tests for tuberculosis

PLoS Med. 2011 Jul;8(7):e1001063. doi: 10.1371/journal.pmed.1001063. Epub 2011 Jul 26.


David Dowdy and colleagues discuss the complexities of costing new TB diagnostic tests, including GeneXpert, and argue that flexible analytic tools are needed for decision-makers to adapt large-sample cost-effectiveness data to local conditions.

Publication types

  • Research Support, N.I.H., Extramural
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Cost-Benefit Analysis
  • False Positive Reactions
  • Humans
  • Molecular Diagnostic Techniques / economics*
  • Mycobacterium tuberculosis / classification
  • Mycobacterium tuberculosis / genetics
  • Mycobacterium tuberculosis / isolation & purification*
  • Polymerase Chain Reaction / economics*
  • Sensitivity and Specificity
  • Tuberculosis, Pulmonary / diagnosis*
  • Tuberculosis, Pulmonary / microbiology